Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Ligand Binding Sites02:40

Ligand Binding Sites

15.7K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
15.7K
Ligand Binding Sites02:40

Ligand Binding Sites

9.1K
9.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ku70-SAP domain has an overlapping function with DNA-PKcs in limiting the lateral movement of the Ku ring along DNA.

Nucleic acids research·2026
Same author

Structural basis of Ku-mediated activation of WRN exonuclease activity.

Nature communications·2026
Same author

CRL2<sup>FEM1B</sup> uses heme to recruit BACH1 for degradation and regulate ferroptosis in lung cancer.

Molecular cell·2026
Same author

Correction to "Near-Equilibrium Unbinding of Streptavidin-Biotin Using Single Molecule Acoustic Force Spectroscopy".

Nano letters·2026
Same author

Human DNA-PKcs promotes broken DNA-end structure independence during NHEJ.

Cell reports·2026
Same author

Identification and functional validation of intracellular protein partners of phosphorothioate splice-switching oligonucleotides using AP-MS.

Molecular therapy. Nucleic acids·2026

Related Experiment Video

Updated: Mar 24, 2026

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source
08:35

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source

Published on: May 29, 2021

7.5K

Structure-Based Virtual Ligand Screening on the XRCC4/DNA Ligase IV Interface.

Grégory Menchon1,2, Oriane Bombarde1,2, Mansi Trivedi1

  • 1Institut de Pharmacologie et de Biologie Structurale, Université de Toulouse, CNRS, UPS, France.

Scientific Reports
|March 12, 2016
PubMed
Summary

Researchers identified the first molecule that disrupts the DNA repair protein complex XRCC4/DNA Ligase IV (Lig4). This finding offers a new strategy to enhance cancer therapy by targeting Non-homologous end-joining (NHEJ) DNA repair.

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.6K
Workflow and Tools for Crystallographic Fragment Screening at the Helmholtz-Zentrum Berlin
06:29

Workflow and Tools for Crystallographic Fragment Screening at the Helmholtz-Zentrum Berlin

Published on: March 3, 2021

6.1K

Related Experiment Videos

Last Updated: Mar 24, 2026

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source
08:35

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source

Published on: May 29, 2021

7.5K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.6K
Workflow and Tools for Crystallographic Fragment Screening at the Helmholtz-Zentrum Berlin
06:29

Workflow and Tools for Crystallographic Fragment Screening at the Helmholtz-Zentrum Berlin

Published on: March 3, 2021

6.1K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Drug Discovery

Background:

  • DNA Ligase IV (Lig4) and XRCC4 form a complex crucial for repairing DNA double-strand breaks (DSBs) via Non-homologous end-joining (NHEJ).
  • Exploiting DSB cytotoxicity is a key strategy in anticancer therapy, making NHEJ a potential drug target.
  • The strong interaction between XRCC4 and Lig4 presents a challenge for drug screening.

Purpose of the Study:

  • To identify molecules that interfere with the XRCC4/Lig4 complex assembly.
  • To develop novel therapeutic strategies for enhancing cancer treatment efficacy.

Main Methods:

  • Molecular Dynamics simulations to identify suitable target regions on Lig4.
  • In silico screening of approximately 95,000 molecules against the Lig4 clamp domain.
  • In vitro validation using Differential Scanning Fluorimetry, Saturation Transfer Difference-NMR, and protein interaction assays.

Main Results:

  • The Lig4 clamp domain was identified as a viable target for inhibiting XRCC4/Lig4 interaction.
  • The first molecule capable of preventing Lig4 binding to XRCC4 in vitro was discovered.
  • This molecule exhibits a unique tripartite interaction with the Lig4 clamp domain.

Conclusions:

  • A novel chemotype was identified for the rational design of inhibitors targeting the XRCC4/Lig4 complex.
  • This discovery opens new avenues for developing drugs to sensitize tumors to clastogenic anticancer treatments by inhibiting NHEJ.